MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix’s theranostic products and external beam radiation therapy (EBRT).

EBRT is a widely used and validated treatment suitable for most solid malignant tumors. This treatment is typically delivered by radiation oncologists who play a central role in managing cancer across multiple stages of the patient journey. The role of EBRT and radiation oncology in treating cancer could potentially be enhanced by integrating with therapeutic radiopharmaceuticals and precision diagnostics. Working with Varian, a key player in EBRT, Telix will explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment. 

The first area of investigational focus is PSMA-PET^[1] imaging for prostate cancer radiotherapy patients. Telix and Varian aim to identify opportunities to utilize Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) and Illuccix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection)^[2]  in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian’s Ethos adaptive radiotherapy), and monitoring responses to treatment. The agreement supports both company-sponsored and investigator-led clinical studies, enabling robust clinical exploration of novel approaches.

While the initial focus is on PSMA imaging, the collaboration has been implemented as a general framework for future co-development opportunities, with broad clinical applicability. This includes other PET imaging candidates in Telix’s pipeline, such as TLX250-CDx (Zircaix®^[3]) and TLX101-CDx (Pixclara®^[3]), as well as potential future therapeutic radiopharmaceuticals. By combining radiopharmaceutical theranostics with Varian’s EBRT technology, the companies believe radiation oncologists are uniquely positioned to lead both definitive and palliative treatment strategies.

Dr. Arthur Kaindl, Head of Varian, said, “Collaborating with Telix opens a powerful pathway to embed precision imaging and theranostics into the radiation therapy workflow, advancing how we personalize and optimize treatment decisions. By combining Telix’s strength in molecular imaging and radiopharmaceuticals with Varian’s leadership in radiation therapy and treatment planning, we are shaping a future of more targeted, patient-focused cancer care.”

Dr. Christian Behrenbruch, Group CEO and Managing Director, Telix, said, “This strategic partnership with Varian represents a transformative opportunity to bring precision imaging into the heart of radiation oncology. Integrating theranostics into EBRT has the potential to improve patient outcomes. And by combining Telix’s innovation in molecular imaging with Varian’s global leadership in cancer treatment technologies, we are building alliances to explore new frontiers in personalized cancer care.”

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix®, Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® has been approved by the United States Food and Drug Administration (FDA)^[4].

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details, and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook

About Varian

At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.) 

Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Telix Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

Varian Media Contact

Kristin Corey
Kristin.Corey@varian.com

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs, including its strategic collaboration with Varian; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

In the news release, Trina Storage and Lightshift Energy Strengthen Strategic Partnership Through Planned Deployment of 1 GWh of Grid-Scale Energy Storage Systems, issued 10-Dec-2025 by Trina Storage over PR Newswire, we are advised by the company that the product name should read “Elementa 2.0 & 2.5” rather than “Elementa Pro” in the second paragraph and the photo and photo caption have been updated, rather than the one as originally issued inadvertently. The complete, corrected release follows:

Trina Storage and Lightshift Energy Strengthen Strategic Partnership Through Planned Deployment of 1 GWh of Grid-Scale Energy Storage Systems

This major milestone reinforces both companies’ long-term commitment to delivering reliable, high-performance energy storage solutions across North America

FREMONT, Calif., Dec. 10, 2025 /PRNewswire/ — Trina Storage, a global leader in energy storage, announced its expanding strategic partnership with Lightshift Energy (Lightshift), a leading U.S. developer, owner, and operator of energy storage systems. This partnership will deliver a portfolio greater than 1 GWh of energy storage projects across the United States.

The portfolio will utilize Trina Storage’s Elementa 2.0 & 2.5 energy storage solution, which is engineered for high efficiency, intrinsic safety, and dependable performance under diverse operating conditions. These installations will support utilities and local communities through enhanced grid stability, peak load management, and flexible capacity as increased power demand and extreme weather threaten grid stability nationwide. The partnership will strengthen Lightshift’s unique position deploying fleets of distribution-connected batteries, enabling fast, scalable delivery and direct support for load growth while improving reliability and generating significant savings for Lightshift’s customers.

Trina Storage and Lightshift have previously demonstrated successful collaboration and strong execution, including four projects in Groton, Holden, and Paxton, Massachusetts in 2024. During a Northeast heatwave, Trina Storage commissioned two sites ahead of schedule, providing critical capacity to local utilities during periods of elevated demand. These results highlighted the effectiveness of coordinated planning, responsive delivery, and consistent system performance in the field.

The continuing partnership and large GWh portfolio highlights Trina Storage’s expertise in U.S. energy storage project engineering, certification, commissioning, and operations. Supported by regional teams and partners, the company delivers local system integration, EMS coordination, grid testing, and onsite commissioning, ensuring efficient project execution and reliable performance.

“We are pleased to continue our collaboration with Lightshift through this significant milestone,” said Doug Alderton, Head of Sales, Trina Storage North America. “Our earlier joint projects demonstrate what our strong partnership can accomplish under demanding conditions. Trina Storage is dedicated to delivering more reliable, flexible energy storage to communities across the U.S. and we look forward to supporting Lightshift in making our shared vision a reality.”

“Lightshift is committed to scaling high-value storage assets that support the reliability and evolution of the U.S. power system,” said Mike Herbert, Managing Partner at Lightshift Energy. “We are proud to continue our work alongside Trina Storage on projects that advance our strategy and reflect our continued focus on delivering solutions that strengthen grid resilience, address load growth, and provide consistent, high-quality performance for the customers and communities we serve.”

As Trina Storage further grows its presence in North America, this expanded partnership highlights the company’s long-term commitment to supporting secure, efficient, and resilient energy infrastructure for the future.

ABU DHABI, UAE, Dec. 11, 2025 /PRNewswire/ — The third day of Abu Dhabi Finance Week (ADFW) 2025, ADGM’s flagship event, featured Fintech Abu Dhabi and RESOLVE, which brought together the world’s most influential leaders in finance, technology, legal and dispute resolution.

Under the overarching theme of ‘Engineering the Capital of Capital’, the day delivered a powerful combination of thought leadership, discussions on disruptive innovation and cutting-edge insights, showcasing Abu Dhabi’s position as a future-focused financial hub and legal powerhouse.

Opening the day, H.E. Hamad Sayah Al Mazrouei, Undersecretary of the Department of Economic Development Abu Dhabi & Chairman, ADGM Academy, said, “The future of finance will not be written by algorithms alone, but by people with vision, courage, and purpose. Through platforms like Fintech Abu Dhabi, we are not only anticipating what’s next for the sector but actively building it. Today’s insightful conversations reflect Abu Dhabi’s ambition to become the launchpad for a new era of inclusive, intelligent, and resilient financial progress.”

Fintech Abu Dhabi: The Next Chapter of Financial Innovation

The ninth edition of Fintech Abu Dhabi, now the MENA region’s largest and most influential fintech gathering, highlighted the seismic shifts that are impacting financial services – from tokenisation and AI to digital banking and stablecoins.

The main stage hosted a series of powerful conversations and high-impact dialogues featuring some of the world’s most influential financial leaders. The line-up included prominent figures from the global fintech ecosystem, such as Brian Armstrong, CEO of Coinbase; Jeremy Allaire, CEO of Circle; Richard Teng, CEO of Binance; Jennifer Johnson, CEO of Franklin Templeton; Anthony Soohoo, CEO of MoneyGram; Ambareen Musa, CEO of GCC, Revolut; and many more.

The sessions explored key topics including digital credit, regulatory innovation, digital assets, institutional adoption and next-gen banking, offering candid insights from fintech CEOs, investors and senior banking executives. The session with Teng examined the volatility of crypto markets and posed the essential question: Can crypto ever mature into trusted infrastructure? Meanwhile, the CEOs of Revolut, Capital.com, Erebor Group and Lukka explored how fintech founders are prioritising speed, regulatory clarity, and trust as they scale in a climate that demands agility and resilience.

Senior banking leaders from State Street, Al Hilal Bank and Piraeus Group discussed how legacy institutions are evolving. From embracing AI to redefining the customer experience, the session provided a candid look at digitisation efforts inside the traditional banking architecture. Early-stage investment experts from FJ Labs and Standard Chartered Ventures unpacked their strategies for identifying billion-dollar startups before they become mainstream by focusing on pattern recognition, pricing discipline, and the emerging science of ‘unicorn’ discovery.

RESOLVE Explores the Theme of ‘Courage‘

In parallel, the fourth edition of RESOLVE 2025 convened under the theme ‘Courage’, focused on international dispute resolution and how legal systems must evolve in the face of rapid digital and market transformation. The forum brought together global legal experts, regulators, business leaders, and policymakers for a dynamic day of keynotes and discussions on cross-border crypto regulation, AI-driven legal strategies, and the legal implications of global capital markets.

H.E. Abdullah Sultan bin Awad Al Nuaimi, UAE Minister of Justice, delivered a compelling keynote on “Justice with Courage”, underscoring Abu Dhabi’s leadership in setting progressive legal standards. ADGM Courts’ Registrar & Chief Executive, Linda Fitz-Alan, opened the forum with a powerful message on navigating legal disruption with clarity and resolve. The day featured a high-calibre speaker lineup, including Matthew Lewis, Managing Director of Hintsa Performance, Netflix Co-Founder and Former CEO, Marc Randolph, and Professor Nancy Gleason of MBZUAI.

Breakout Events, Newcomers, Major Collaborations and Announcements

Running alongside the main events were other breakout events such as the AI Abu Dhabi Forum, Blockchain Abu Dhabi, Risk 4.0 Forum, Bloomberg’s event on The AI Evolution: From Potential to Practicality,  and Eastpoint Digital Assets Forum. Throughout the day, closed-door summits such as the Web3 Leaders Roundtable – Presented by ADGM Emerging Tech and #Hashed and Stablecoin Dialogues were held with senior executives.

The third day of ADFW witnessed announcements from Galaxy Digital and the Eurasian Development Bank (EDB), which are setting up offices in ADGM. Another notable announcement for the day came from SAAS Properties, which officially unveiled its newest project – The Ritz-Carlton Residences, Al Maryah Island.

A total of 24 Memorandums of Understanding (MoU) were announced during the third day of ADFW. Partnerships were signed between local and international entities such as Blackrock, Finstreet, Swiss Re, RIQ, Kitopi Global, Lulu Financial Group, Crypto.com, 42 Abu Dhabi, Hanwha and Kresus.

ADFW continues for a final day with its featured event – Abu Dhabi Sustainable Finance Forum (ADSFF), and other key events will focus on sustainability and finance.

For more details on ADFW, visit www.adfw.com.

SHENZHEN, China, Dec. 11, 2025 /PRNewswire/ — Shenzhen Creality 3D Technology Co., Ltd. (“Creality”), a global provider of 3D printing and 3D scanning solutions, has recently officially announced a strategic partnership with KVS Ltd, developer of the QUICKSURFACE reverse-engineering platform. The collaboration introduces an integrated workflow that streamlines the entire process from 3D scanning to CAD reconstruction for engineering, product design, and manufacturing applications.

Creality’s 3D scanner lineup — including the Raptor, Otter, and Sermoon series — offers up to 0.02 mm accuracy, high-speed capture, and multi-mode scanning, enabling users to digitize complex parts with precision. When combined with QUICKSURFACE, engineers can efficiently transform point clouds and mesh data into editable, manufacturable CAD models. The unified workflow supports key use cases such as reverse engineering, part restoration, product redesign, and rapid prototyping.

“Our partnership with QUICKSURFACE strengthens Creality’s commitment to delivering complete and accessible 3D solutions,” said Ross Luo, Head of 3D Scanner BU at Creality. “Together, we provide users with a professional, streamlined path from physical objects to engineering-ready digital assets.”

To mark the launch, Creality is offering a limited-time 20% discount on QUICKSURFACE Lite and Pro licenses purchased through the Creality Store. More information is available at:
https://store.creality.com/products/quicksurface-lite-pro

About Creality

Creality is a global leader in 3D printing and 3D scanning solutions, serving consumer and professional markets since 2014. With a focus on accessible, high-performance digital manufacturing tools, Creality empowers millions of users worldwide. Learn more at www.creality.com.

About KVS / QUICKSURFACE

KVS develops the QUICKSURFACE software suite for professional reverse engineering, helping users convert scan data into precise CAD models efficiently. The company supports engineers worldwide with flexible, high-accuracy solutions. Visit www.quicksurface.com.

Three Consecutive CES Innovation Awards Accelerate North American Market Expansion

Humanoid Robot ALLEX to Make Its First Global Appearance at CES 2026

SEOUL, South Korea, Dec. 11, 2025 /PRNewswire/ — WIRobotics, a global robotics technology company, announced that it will present a hands-on demonstration of its wearable walking-assist robot WIM S at CES 2026 Unveiled in Las Vegas on January 4.

CES Unveiled is an official preview event where global media and industry professionals explore key technologies ahead of the main exhibition. At the event, WIRobotics will offer attendees the opportunity to wear and walk with WIM S, first released in Korea in 2025. The demonstration is designed to allow participants to experience the device’s enhanced comfort and responsive assistive performance, underscoring the rising global potential of wearable robotics.

WIRobotics received CES Innovation Awards for three consecutive years—Robotics / Accessibility & Aging Tech (2024), Robotics (2025), and Digital Health (2026) for WIM KIDS, a model designed for children.

The WIM series is used by seniors, people with limited mobility, and workers who require endurance or musculoskeletal support. Its global presence continues to grow across Korea, Mainland China, Japan, Italy, and the Netherlands.

The WIM S model showcased at Unveiled features major upgrades, including a lighter and more compact form factor for improved portability and comfort. User feedback (VOC) was incorporated to enhance both assistive responsiveness and overall ease of use. WIM S supports four walking modes—Air, Hiking, Care, and Aqua—allowing users to benefit from the device in a wide range of situations, from everyday walking to hiking and strength-focused exercise.

CES 2026 Unveiled will take place from 4:00 p.m. to 7:00 p.m. on January 4 at Mandalay Bay Level 2, Shoreline Exhibit Hall. WIRobotics will offer interactive walking sessions featuring WIM S throughout the event. During the main CES exhibition at the Venetian Expo (Hall A–D), Booth #54735, the company will also present the first global showcase of ALLEX, an upper-body humanoid robot introduced in August 2025.

“CES Unveiled is where global media first encounter the breakthrough technologies that signal the direction of the year ahead,” said Yeonbaek Lee, Co-CEO of WIRobotics. “The fully re-engineered WIM S and the CES debut of our upper-body humanoid ALLEX mark a turning point that introduces a new paradigm for the next generation of robotic technology WIRobotics aims to lead.”

About WIRobotics
WIRobotics (We Innovate Robotics) is a global robotics innovator enhancing human mobility and everyday life. With its WIM series recognized with CES Innovation Awards for three consecutive years and its next-generation humanoid robot ALLEX, the company integrates human-centered design with advanced engineering, leading the transition toward a “one person, one robot” era.

For more information,
Youtube: https://www.youtube.com/@WIRobotics
Linkedin: https://www.linkedin.com/company/103004622
TikTok: https://www.tiktok.com/@wirobotics